Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RP902
- Development stage
- Phase 2
- Lead developer
- Risen
- Modality
- Small Molecules
01
Overview
RP902 is a small molecule therapeutic being developed by Risen Shanghai Medical Technology (also known as Risen Pharma) for the treatment of Alzheimer's disease. The drug is designed to target Apolipoprotein E4 (APOE4), which is recognized as the most significant genetic risk factor for late-onset Alzheimer's disease. APOE4 is involved in the aggregation and reduced clearance of amyloid-beta plaques, as well as tau-mediated neurodegeneration. RP902 acts as a modulator of the APOE4 protein to potentially slow or prevent disease progression. As of the latest pipeline updates, RP902 is in the IND-enabling stage of development.
02
Targets
APOE4 (Apolipoprotein E4)
Beyond the preview
Go deeper on RP902.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RP902.